PHAXIAM Therapeutics S.A. (0QSS.L)
EUR 1.76
(1.03%)
EUR 1.76
(1.03%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 7.03 Million EUR | -6.35% |
| 2022 | 7.5 Million EUR | -24.27% |
| 2021 | 9.91 Million EUR | -30.89% |
| 2020 | 14.34 Million EUR | 985.84% |
| 2019 | 1.32 Million EUR | 6.28% |
| 2018 | 1.24 Million EUR | -37.22% |
| 2017 | 1.98 Million EUR | -29.69% |
| 2016 | 2.81 Million EUR | 1764.9% |
| 2015 | 151 Thousand EUR | -65.37% |
| 2014 | 435.99 Thousand EUR | -40.32% |
| 2013 | 730.54 Thousand EUR | -88.58% |
| 2012 | 6.39 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - EUR | -100.0% |
| 2024 Q2 | 5.19 Million EUR | 0.0% |
| 2023 Q1 | 11.11 Million EUR | 48.01% |
| 2023 FY | 7.03 Million EUR | -6.35% |
| 2023 Q3 | - EUR | -100.0% |
| 2023 Q4 | 9.37 Million EUR | 0.0% |
| 2023 Q2 | 8.55 Million EUR | -23.03% |
| 2022 Q2 | 12.76 Million EUR | 0.0% |
| 2022 Q1 | - EUR | -100.0% |
| 2022 Q3 | - EUR | -100.0% |
| 2022 Q4 | 7.5 Million EUR | 0.0% |
| 2021 Q1 | - EUR | -100.0% |
| 2021 Q2 | 14.45 Million EUR | 0.0% |
| 2021 Q4 | 9.91 Million EUR | 0.0% |
| 2020 Q2 | 4.35 Million EUR | 0.0% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 Q4 | 14.34 Million EUR | 0.0% |
| 2019 Q3 | 13.19 Million EUR | 913.21% |
| 2019 Q4 | 1.32 Million EUR | -89.99% |
| 2019 Q2 | 1.3 Million EUR | 0.0% |
| 2019 Q1 | - EUR | -100.0% |
| 2018 Q4 | 1.24 Million EUR | 0.0% |
| 2018 Q2 | 1.63 Million EUR | 0.0% |
| 2018 Q1 | - EUR | -100.0% |
| 2017 Q4 | 2.01 Million EUR | 0.0% |
| 2017 Q1 | - EUR | -100.0% |
| 2017 Q2 | 2.42 Million EUR | 0.0% |
| 2016 Q2 | 126 Thousand EUR | 0.0% |
| 2016 Q1 | - EUR | -100.0% |
| 2016 Q4 | 2.81 Million EUR | 0.0% |
| 2016 Q3 | 2.81 Million EUR | 2134.92% |
| 2015 Q2 | 144.45 Thousand EUR | 0.0% |
| 2015 Q1 | 144.45 Thousand EUR | -66.87% |
| 2015 Q3 | 151 Thousand EUR | 4.53% |
| 2015 Q4 | 151 Thousand EUR | 0.0% |
| 2014 Q4 | 435.99 Thousand EUR | 0.0% |
| 2014 Q2 | 618.91 Thousand EUR | 0.0% |
| 2014 Q1 | 618.91 Thousand EUR | -15.28% |
| 2014 Q3 | 435.99 Thousand EUR | -29.55% |
| 2013 Q3 | 730.54 Thousand EUR | 0.0% |
| 2013 Q1 | - EUR | -100.0% |
| 2013 Q4 | 730.54 Thousand EUR | 0.0% |
| 2012 Q4 | 6.39 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Boiron SA | 6.64 Million EUR | -5.794% |
| Laboratorios Farmaceuticos Rovi, S.A. | 38.57 Million EUR | 81.776% |
| Vetoquinol SA | 9.66 Million EUR | 27.248% |
| Valneva SE | 132.76 Million EUR | 94.705% |
| AB Science S.A. | 16.98 Million EUR | 58.618% |
| Nanobiotix S.A. | 41.66 Million EUR | 83.125% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |
| BioSenic S.A. | 15.57 Million EUR | 54.858% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 84.272% |
| Formycon AG | 7.81 Million EUR | 10.045% |